<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367794</url>
  </required_header>
  <id_info>
    <org_study_id>GO29437</org_study_id>
    <secondary_id>2014-003208-59</secondary_id>
    <nct_id>NCT02367794</nct_id>
  </id_info>
  <brief_title>A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]</brief_title>
  <official_title>A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, open-label study will evaluate the safety and efficacy of atezolizumab
      (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel
      compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants
      with Stage IV squamous NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 11, 2015</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 3, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population</measure>
    <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
    <description>PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) in the ITT Population</measure>
    <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
    <description>OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS in the Tumor Gene Expression (tGE) Population</measure>
    <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as Determined by the Investigator Using RECIST v1.1 in the tGE Population</measure>
    <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population</measure>
    <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population</measure>
    <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in the TC2/3 or IC2/3 Population</measure>
    <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in the TC1/2/3 or IC1/2/3 Population</measure>
    <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population</measure>
    <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population</measure>
    <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS at 1 and 2 Years in the ITT Population</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>OS rates at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population</measure>
    <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population</measure>
    <time_frame>Up to approximately 30 months after the first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population</measure>
    <time_frame>Baseline up to approximately 30 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A vs. Arm B)</measure>
    <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in the ITT Population (Arm A vs. Arm B)</measure>
    <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab</measure>
    <time_frame>Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 39 months), at treatment discontinuation (up to 39 months), and at 120 days after the last dose of atezolizumab (up to approximately 39 months, each cycle is 21 days)</time_frame>
    <description>The predose samples will be collected on the same day of treatment administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Atezolizumab Concentration (Cmax)</measure>
    <time_frame>Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle up to 39 months; 30 minutes postdose on Day 1 of Cycles 1 and 3; at treatment discontinuation (up to 39 months), and at 120 days after last dose of atezolizumab (up to 39 months, each cycle is 21 days)</time_frame>
    <description>The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Atezolizumab Concentration (Cmin)</measure>
    <time_frame>Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 39 months), at treatment discontinuation (up to 39 months), and at 120 days after the last dose of atezolizumab (up to approximately 39 months, each cycle is 21 days)</time_frame>
    <description>The predose samples will be collected on the same day of treatment administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Paclitaxel</measure>
    <time_frame>Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Nab-Paclitaxel</measure>
    <time_frame>Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Carboplatin</measure>
    <time_frame>Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1021</enrollment>
  <condition>Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Atezolizumab + Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Nab-Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody</intervention_name>
    <description>Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm A: Atezolizumab + Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_label>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.</description>
    <arm_group_label>Arm A: Atezolizumab + Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_label>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_label>Arm C: Nab-Paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.</description>
    <arm_group_label>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_label>Arm C: Nab-Paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.</description>
    <arm_group_label>Arm A: Atezolizumab + Paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC

          -  Previously obtained archival tumor tissue or tissue obtained from biopsy at screening

          -  Measurable disease as defined by RECIST v1.1

          -  Adequate hematologic and end organ function

        Exclusion Criteria:

          -  Active or untreated central nervous system (CNS) metastasis

          -  Malignancies other than NSCLC within 5 years prior to randomization, with the
             exception of those with a negligible risk of metastasis or death treated with expected
             curative outcome

          -  Pregnant or lactating women

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation
             field (fibrosis) is permitted

          -  Positive test for Human Immunodeficiency Virus (HIV)

          -  Active hepatitis B or hepatitis C

          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune
             checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1
             therapeutic antibody

          -  Severe infection within 4 weeks prior to randomization

          -  Significant history of cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ironwood Cancer &amp; Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern CA Permanente Med Grp</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Sacramento Medical Center and Medical Offices</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Leandro Medical Center</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente; Oncology Clinical Trials</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Walnut Creek</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital Inc</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI Florida Cancer Specialists South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC; Research</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers P.C.</name>
      <address>
        <city>Carrollton</city>
        <state>Georgia</state>
        <zip>30117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Georgia Cancer Care PC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Regional Medical Center, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology; Associates, Ltd.</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quincy Medical Group</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Med Oncology &amp; Hematology Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology; Associates of the Quad Cities</name>
      <address>
        <city>Bettendorf</city>
        <state>Iowa</state>
        <zip>52722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology/Oncology</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Med Ctr</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southcoast Health System; Southcoast Centers For Cancer Care</name>
      <address>
        <city>Fairhaven</city>
        <state>Massachusetts</state>
        <zip>02719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Regional Cancer Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates at Bridgepoint</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Va Sierra Nevada Health Care System</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Hospital; Oncology Research</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates LLC</name>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <zip>08080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W.G. Bill Hefner VA Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45203-0542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark H. Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Hamilton</city>
        <state>Ohio</state>
        <zip>45103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Medical Center Bend; Cancer Care Of The Cascades</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Uni</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Care Associates</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology (Lanham) - USOR</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pittsburgh Medical Ctr</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI Tennessee Oncology Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI The Center For Cancer and Blood Disorders</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer Partnership</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación CENIT para la Investigación en Neurociencias</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral (CORI)</name>
      <address>
        <city>La Rioja</city>
        <zip>F5300COE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Pergamino</name>
      <address>
        <city>Pergamino</city>
        <zip>2700</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Koriza</name>
      <address>
        <city>Santa Rosa</city>
        <zip>6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion; Clinica - Clinica Viedma S.A.</name>
      <address>
        <city>Viedma</city>
        <zip>R8500ACE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle; Medical Oncology</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital Malvern</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medizinische Privatuniversität</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Werken Glorieux VZW</name>
      <address>
        <city>Ronse</city>
        <zip>9600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cenantron - Centro Avancado de Tratamento Oncologico</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30130-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica</name>
      <address>
        <city>Londrina</city>
        <state>PR</state>
        <zip>86 015 520</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liga Norte Riograndense Contra O Câncer</name>
      <address>
        <city>Natal</city>
        <state>RN</state>
        <zip>59040150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPCEM; Instituto de Pesquisa de Estudos Multicêntricos</name>
      <address>
        <city>Caxias do Sul</city>
        <state>RS</state>
        <zip>95070-560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bruno Born</name>
      <address>
        <city>Lajeado</city>
        <state>RS</state>
        <zip>95900-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mae de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFRGS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>*X*Fundação Pio XII Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de Sao Jose do Rio Preto</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Do Cancer A C Camargo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01525-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Central Onco Hospital OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Serdika EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Osler Health Centre</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9V 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Center</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cite de La Sante de Laval; Hemato-Oncologie</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve - Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Jerome Medical Research Inc</name>
      <address>
        <city>St. Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health &amp; Care SPA</name>
      <address>
        <city>Santiago</city>
        <zip>7500006</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedad de Investigaciones Medicas Ltda (SIM)</name>
      <address>
        <city>Temuco</city>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Clémentville</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de La Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Pontchaillou; Service de Pneumologie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Sud Reunion; Service de Pneumologie</name>
      <address>
        <city>Saint Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Saint Quentin</name>
      <address>
        <city>Saint Quentin</city>
        <zip>2100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées de Sainte Anne; Service Pharmacie Essais Cliniques</name>
      <address>
        <city>Toulon Cedex 9</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie</name>
      <address>
        <city>Bielefeld</city>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot; der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabethen Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie</name>
      <address>
        <city>Gerlingen</city>
        <zip>70839</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LungenClinic Großhansdorf GmbH</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria; Halle-Dolau gGmbH</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Des Saarlandes; Klinik für Innere Medizin V</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik für Lungenerkrankungen</name>
      <address>
        <city>Immenhausen</city>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Koln gGmbH</name>
      <address>
        <city>Koln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen; Klinik für Pneumologie und Pneumologische Onkologie</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Bruder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftung Mathias-Spital Rheine</name>
      <address>
        <city>Rheine</city>
        <zip>48431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital - Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center; Oncology</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tiqwa</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center; Oncology Dept</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corporation; Oncology Institute</name>
      <address>
        <city>Rambam</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Ctr; Oncology</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <state>Campania</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN A Cardarelli</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Seconda Università degli Studi di Napoli; Farmacia Centralizzata</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL 3 Genovese; DSM</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Giovanni Paolo II Istituto Oncologico</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile - Livorno</name>
      <address>
        <city>Livorno</city>
        <state>Toscana</state>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Silvestrini</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital; Respiratory Medicine</name>
      <address>
        <city>Aichi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital; Respiratory Medicine</name>
      <address>
        <city>Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East; Thoracic Oncology</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center; Internal Medicine</name>
      <address>
        <city>Ehime</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital; Respiratory</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital; Respiratory Medicine</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Himeji Medical Center</name>
      <address>
        <city>Hyogo</city>
        <zip>670-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center; Thoracic Oncology</name>
      <address>
        <city>Hyogo</city>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital; Division of respiratory</name>
      <address>
        <city>Ibaraki</city>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center;Thoracic Oncology</name>
      <address>
        <city>Kanagawa</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital, Respiratory Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital; Pulmonary Medicine</name>
      <address>
        <city>Miyagi</city>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital; Respiratory Medicine and Infectious Disease</name>
      <address>
        <city>Niigata</city>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital; Respiratory and Allergy Medicine</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute; Thoracic Oncology</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City Uni Hospital; Respiratory Medicine</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Medical university Hospital; Thoracic Oncology</name>
      <address>
        <city>Osaka</city>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Habikino Medical Center</name>
      <address>
        <city>Osaka</city>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center; Thoracic Oncology</name>
      <address>
        <city>Saitama</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kinki-Chuo Chest Medical Center</name>
      <address>
        <city>Sakai-shi</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center; Thoracic Oncology</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital; Thoracic Medical Oncology</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital; Dept of Surgery</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital Latvian Oncology Centre</name>
      <address>
        <city>Riga</city>
        <zip>LV-1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Rīga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <zip>08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Universitario Contra El Cancer</name>
      <address>
        <city>Monterrey</city>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancerología</name>
      <address>
        <city>Queretaro</city>
        <zip>76090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum; VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>EDE</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital; Afdeling Longgeneeskunde en Tuberculose</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis; R&amp;D Long</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Monte Carmelo</name>
      <address>
        <city>Arequipa</city>
        <zip>04001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Guillermo Almenara Irigoyen ESSALUD</name>
      <address>
        <city>Lima</city>
        <zip>Lima 13</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Regional de Enfermedades Neoplásicas Del Norte</name>
      <address>
        <city>Trujillo</city>
        <zip>12345</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPO de Lisboa; Servico de Pneumologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulido Valente; Servico de Pneumologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1796-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto - Hospital de Santo António</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sao Joao; Servico de Pneumologia</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Oncology Hospital #62</name>
      <address>
        <city>Moscovskaya Oblast</city>
        <state>Moskovskaja Oblast</state>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncology Research Center n.a. N.N. Blokhin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Dispensary</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny onkologicky ustav</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>POKO Poprad s.r.o.</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli; Servicio de Oncologia</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de Oncologia</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>LA Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Insular-Materno Infantil</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>LAS Palmas</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Senora de Valme</name>
      <address>
        <city>Seville</city>
        <state>Sevilla</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>S. Cristobal De La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Augusti; Servicio de Oncologia</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>280146</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital; Hematology-Oncology</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital; Department of Urology</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center Liou Ying Campus</name>
      <address>
        <city>Liuying Township</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Chiayi</name>
      <address>
        <city>Putzu</city>
        <zip>613</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Uni Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Katerynoslav Governorate</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MNPE Zaporizhzhia Regional Antitumor Center ZRC</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Katerynoslav Governorate</state>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkiv Governorate</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council</name>
      <address>
        <city>Vinnytsia</city>
        <state>KIEV Governorate</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MI of the Lviv Regional Council Lviv Oncology Regional Treatment and Diagnostic Centre; Chemotherapy</name>
      <address>
        <city>Lviv</city>
        <state>Volhynian Governorate</state>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary; Surgery Department #1</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department</name>
      <address>
        <city>Kryvyi Rih</city>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Sumy</city>
        <zip>40005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Transcarpathian Regional Clinical Oncology Dispensary; Chemotherapy Department</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod Central City Clinical Hospital</name>
      <address>
        <city>Uzhhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>September 25, 2019</results_first_submitted>
  <results_first_submitted_qc>October 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2019</results_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02367794/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02367794/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm C: Nab-Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
        </group>
        <group group_id="P3">
          <title>Arm A: Atezolizumab + Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="343"/>
                <participants group_id="P3" count="338"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="240"/>
                <participants group_id="P3" count="249"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="223"/>
                <participants group_id="P3" count="229"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Brain metastasis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient unable to receive carboplatin</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypercalcemia prior to C1D1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm C: Nab-Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
        </group>
        <group group_id="B3">
          <title>Arm A: Atezolizumab + Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="340"/>
            <count group_id="B2" value="343"/>
            <count group_id="B3" value="338"/>
            <count group_id="B4" value="1021"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="8.1"/>
                    <measurement group_id="B2" value="64.0" spread="9.2"/>
                    <measurement group_id="B3" value="65.0" spread="8.3"/>
                    <measurement group_id="B4" value="64.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="278"/>
                    <measurement group_id="B4" value="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="306"/>
                    <measurement group_id="B3" value="297"/>
                    <measurement group_id="B4" value="902"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="289"/>
                    <measurement group_id="B3" value="290"/>
                    <measurement group_id="B4" value="869"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population</title>
        <description>PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.</description>
        <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
        <population>Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C: Nab-Paclitaxel + Carboplatin</title>
            <description>The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</title>
            <description>The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
          </group>
          <group group_id="O3">
            <title>Arm A: Atezolizumab + Paclitaxel + Carboplatin</title>
            <description>The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population</title>
          <description>PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.</description>
          <population>Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="5.5" upper_limit="5.7"/>
                    <measurement group_id="O2" value="6.5" lower_limit="5.7" upper_limit="7.1"/>
                    <measurement group_id="O3" value="5.6" lower_limit="5.5" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) in the ITT Population</title>
        <description>OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.</description>
        <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
        <population>Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C: Nab-Paclitaxel + Carboplatin</title>
            <description>The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</title>
            <description>The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
          </group>
          <group group_id="O3">
            <title>Arm A: Atezolizumab + Paclitaxel + Carboplatin</title>
            <description>The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in the ITT Population</title>
          <description>OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.</description>
          <population>Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="12.2" upper_limit="15.1"/>
                    <measurement group_id="O2" value="14.2" lower_limit="12.3" upper_limit="16.8"/>
                    <measurement group_id="O3" value="12.6" lower_limit="11.6" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1581</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in the Tumor Gene Expression (tGE) Population</title>
        <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS as Determined by the Investigator Using RECIST v1.1 in the tGE Population</title>
        <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population</title>
        <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population</title>
        <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in the TC2/3 or IC2/3 Population</title>
        <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in the TC1/2/3 or IC1/2/3 Population</title>
        <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population</title>
        <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population</title>
        <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS at 1 and 2 Years in the ITT Population</title>
        <description>OS rates at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population</description>
        <time_frame>1 and 2 years</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population</title>
        <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population</title>
        <time_frame>Up to approximately 30 months after the first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population</title>
        <time_frame>Baseline up to approximately 30 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A vs. Arm B)</title>
        <time_frame>Up to approximately 30 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in the ITT Population (Arm A vs. Arm B)</title>
        <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <time_frame>Up to approximately 39 months after first participant enrolled</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab</title>
        <description>The predose samples will be collected on the same day of treatment administration.</description>
        <time_frame>Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 39 months), at treatment discontinuation (up to 39 months), and at 120 days after the last dose of atezolizumab (up to approximately 39 months, each cycle is 21 days)</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Atezolizumab Concentration (Cmax)</title>
        <description>The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.</description>
        <time_frame>Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle up to 39 months; 30 minutes postdose on Day 1 of Cycles 1 and 3; at treatment discontinuation (up to 39 months), and at 120 days after last dose of atezolizumab (up to 39 months, each cycle is 21 days)</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Serum Atezolizumab Concentration (Cmin)</title>
        <description>The predose samples will be collected on the same day of treatment administration.</description>
        <time_frame>Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 39 months), at treatment discontinuation (up to 39 months), and at 120 days after the last dose of atezolizumab (up to approximately 39 months, each cycle is 21 days)</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Paclitaxel</title>
        <time_frame>Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Nab-Paclitaxel</title>
        <time_frame>Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Carboplatin</title>
        <time_frame>Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first study drug administration to the data cutoff date: 3 October 2018 (up to approximately 40 months).</time_frame>
      <desc>Safety-evaluable population included all participants who received at least one dose of any study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm C: Nab-Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
        </group>
        <group group_id="E3">
          <title>Arm A: Atezolizumab + Paclitaxel + Carboplatin</title>
          <description>The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA Version 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="229" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="160" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ferbrile Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Atrial Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-Oesophageal Fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Anal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Duodenal Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Performance Status Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Drug-Induced Liver Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Immune-Medicated Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haemophagocytic Lymphohistiocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Clostridium Difficle Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Colonic Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Enterocolitis Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Infected Dermal Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Infection Exacerbation of Chronic Obstructive Ariways Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pleural Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="334"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E3" events="27" subjects_affected="25" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia Haemophilus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia Staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia Streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pseudomonal Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pulmonary Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Stomatococcal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chest Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fermur Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Periorbital Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Radiation Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Radiation Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rib Facture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Toxicity to Various Agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Blood Lactic Acid Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>General Physical Condition Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Polymyositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Salivary Gland Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gallbladder Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Infected Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tumour Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Embolic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Motor Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Myxoedema Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Suicide Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bronchial Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diaphragmatic Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dyspnoea at Rest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Laryngeal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung Consolidation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Paranasal Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumothorax Spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Therapeutic Embolisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haemodynamic Instability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Superior Vena Cava Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MeDRA Version 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="325" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="315" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="244" subjects_affected="193" subjects_at_risk="334"/>
                <counts group_id="E2" events="250" subjects_affected="186" subjects_at_risk="334"/>
                <counts group_id="E3" events="154" subjects_affected="128" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="54" subjects_affected="34" subjects_at_risk="334"/>
                <counts group_id="E2" events="86" subjects_affected="42" subjects_at_risk="334"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="212" subjects_affected="122" subjects_at_risk="334"/>
                <counts group_id="E2" events="260" subjects_affected="121" subjects_at_risk="334"/>
                <counts group_id="E3" events="59" subjects_affected="42" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="170" subjects_affected="92" subjects_at_risk="334"/>
                <counts group_id="E2" events="161" subjects_affected="90" subjects_at_risk="334"/>
                <counts group_id="E3" events="66" subjects_affected="46" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="334"/>
                <counts group_id="E3" events="26" subjects_affected="25" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="334"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="84" subjects_affected="72" subjects_at_risk="334"/>
                <counts group_id="E2" events="124" subjects_affected="101" subjects_at_risk="334"/>
                <counts group_id="E3" events="93" subjects_affected="75" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="107" subjects_affected="77" subjects_at_risk="334"/>
                <counts group_id="E2" events="128" subjects_affected="88" subjects_at_risk="334"/>
                <counts group_id="E3" events="114" subjects_affected="93" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="136" subjects_affected="96" subjects_at_risk="334"/>
                <counts group_id="E2" events="197" subjects_affected="129" subjects_at_risk="334"/>
                <counts group_id="E3" events="133" subjects_affected="93" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="334"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="334"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="59" subjects_affected="48" subjects_at_risk="334"/>
                <counts group_id="E2" events="78" subjects_affected="63" subjects_at_risk="334"/>
                <counts group_id="E3" events="62" subjects_affected="49" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="85" subjects_affected="66" subjects_at_risk="334"/>
                <counts group_id="E2" events="79" subjects_affected="58" subjects_at_risk="334"/>
                <counts group_id="E3" events="99" subjects_affected="77" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E2" events="29" subjects_affected="24" subjects_at_risk="334"/>
                <counts group_id="E3" events="29" subjects_affected="27" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="101" subjects_affected="88" subjects_at_risk="334"/>
                <counts group_id="E2" events="127" subjects_affected="103" subjects_at_risk="334"/>
                <counts group_id="E3" events="109" subjects_affected="95" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="334"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="334"/>
                <counts group_id="E3" events="27" subjects_affected="22" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="34" subjects_at_risk="334"/>
                <counts group_id="E2" events="65" subjects_affected="44" subjects_at_risk="334"/>
                <counts group_id="E3" events="63" subjects_affected="44" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E3" events="27" subjects_affected="17" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E3" events="34" subjects_affected="22" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E3" events="23" subjects_affected="15" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="334"/>
                <counts group_id="E2" events="39" subjects_affected="25" subjects_at_risk="334"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E2" events="61" subjects_affected="40" subjects_at_risk="334"/>
                <counts group_id="E3" events="53" subjects_affected="33" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E2" events="60" subjects_affected="34" subjects_at_risk="334"/>
                <counts group_id="E3" events="50" subjects_affected="30" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E3" events="33" subjects_affected="25" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="334"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="145" subjects_affected="65" subjects_at_risk="334"/>
                <counts group_id="E2" events="132" subjects_affected="60" subjects_at_risk="334"/>
                <counts group_id="E3" events="24" subjects_affected="17" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="110" subjects_affected="59" subjects_at_risk="334"/>
                <counts group_id="E2" events="125" subjects_affected="59" subjects_at_risk="334"/>
                <counts group_id="E3" events="64" subjects_affected="40" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="334"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="334"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="68" subjects_affected="36" subjects_at_risk="334"/>
                <counts group_id="E2" events="64" subjects_affected="32" subjects_at_risk="334"/>
                <counts group_id="E3" events="19" subjects_affected="12" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="98" subjects_affected="84" subjects_at_risk="334"/>
                <counts group_id="E2" events="107" subjects_affected="83" subjects_at_risk="334"/>
                <counts group_id="E3" events="106" subjects_affected="92" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" events="33" subjects_affected="23" subjects_at_risk="334"/>
                <counts group_id="E3" events="30" subjects_affected="20" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E3" events="28" subjects_affected="25" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="334"/>
                <counts group_id="E2" events="35" subjects_affected="28" subjects_at_risk="334"/>
                <counts group_id="E3" events="30" subjects_affected="24" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="38" subjects_at_risk="334"/>
                <counts group_id="E2" events="78" subjects_affected="53" subjects_at_risk="334"/>
                <counts group_id="E3" events="40" subjects_affected="35" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="334"/>
                <counts group_id="E2" events="51" subjects_affected="38" subjects_at_risk="334"/>
                <counts group_id="E3" events="80" subjects_affected="61" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E2" events="40" subjects_affected="36" subjects_at_risk="334"/>
                <counts group_id="E3" events="35" subjects_affected="31" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E3" events="34" subjects_affected="22" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="334"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="334"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="334"/>
                <counts group_id="E3" events="62" subjects_affected="43" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="334"/>
                <counts group_id="E3" events="46" subjects_affected="35" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="41" subjects_affected="32" subjects_at_risk="334"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="334"/>
                <counts group_id="E3" events="33" subjects_affected="31" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="334"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E3" events="43" subjects_affected="37" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripherial</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="334"/>
                <counts group_id="E2" events="39" subjects_affected="34" subjects_at_risk="334"/>
                <counts group_id="E3" events="73" subjects_affected="66" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="334"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E3" events="31" subjects_affected="26" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E2" events="54" subjects_affected="48" subjects_at_risk="334"/>
                <counts group_id="E3" events="68" subjects_affected="55" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="334"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E3" events="31" subjects_affected="29" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="61" subjects_affected="51" subjects_at_risk="334"/>
                <counts group_id="E2" events="74" subjects_affected="59" subjects_at_risk="334"/>
                <counts group_id="E3" events="67" subjects_affected="59" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="65" subjects_affected="57" subjects_at_risk="334"/>
                <counts group_id="E2" events="94" subjects_affected="66" subjects_at_risk="334"/>
                <counts group_id="E3" events="72" subjects_affected="61" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="43" subjects_affected="37" subjects_at_risk="334"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="334"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E2" events="28" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="103" subjects_affected="102" subjects_at_risk="334"/>
                <counts group_id="E2" events="113" subjects_affected="113" subjects_at_risk="334"/>
                <counts group_id="E3" events="134" subjects_affected="130" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="334"/>
                <counts group_id="E2" events="29" subjects_affected="20" subjects_at_risk="334"/>
                <counts group_id="E3" events="42" subjects_affected="32" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E2" events="47" subjects_affected="42" subjects_at_risk="334"/>
                <counts group_id="E3" events="53" subjects_affected="41" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" events="25" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

